PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.42%
Revenue growth below 50% of CRWD's 5.94%. Michael Burry would check for competitive disadvantage risks.
No Data
No Data available this quarter, please select a different quarter.
1.42%
Gross profit growth below 50% of CRWD's 5.45%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-221.14%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-219.44%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-221.14%
Operating income decline while CRWD shows 9.37% growth. Joel Greenblatt would examine position.
-219.44%
Operating margin decline while CRWD shows 14.45% growth. Joel Greenblatt would examine position.
221.14%
Other expenses growth above 1.5x CRWD's 18.80%. Michael Burry would check for concerning trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
EPS decline while CRWD shows 29.55% growth. Joel Greenblatt would examine position.
-100.00%
Diluted EPS decline while CRWD shows 29.55% growth. Joel Greenblatt would examine position.
3.28%
Share count reduction below 50% of CRWD's 0.59%. Michael Burry would check for concerns.
3.28%
Diluted share reduction below 50% of CRWD's 0.59%. Michael Burry would check for concerns.